Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tilapia mossambica source streptococcus agalactiae low virulent strain and application thereof

A technology for Streptococcus nisca and tilapia, which is applied to bacteria, antibacterial drugs, bacterial antigen components, etc., can solve the problems of inconvenient immunization routes, high immunization prevention and control costs, and short immunization protection period, so as to achieve high-efficiency immune protection, Good immune protection and infection protection

Active Publication Date: 2014-11-19
GUANGXI ACADEMY OF FISHERY SCI
View PDF3 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The purpose of the present invention is to solve the problems of high cost of immunization prevention and control of tilapia streptococcosis inactivated vaccine, short immunization protection period, inconvenient immunization route, etc., to provide attenuated strains of Streptococcus agalactiae derived from tilapia and its application, and to develop tilapia Streptococcus disease attenuated live vaccine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tilapia mossambica source streptococcus agalactiae low virulent strain and application thereof
  • Tilapia mossambica source streptococcus agalactiae low virulent strain and application thereof
  • Tilapia mossambica source streptococcus agalactiae low virulent strain and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Embodiment 1 Bacterial strain and medium used in the present invention

[0014] The wild type strain HN016 of Streptococcus agalactiae derived from tilapia was isolated from the brain of a tilapia farm where streptococcal disease broke out in southern my country. ).

[0015] The attenuated strain YM001 of Streptococcus agalactiae derived from tilapia was obtained by attenuating the wild-type strain HN016 by using the rapid culture and attenuating method of temperature difference subculture.

[0016] Tryptone broth (TSB): tryptone 17.0 g / L, soybean peptone 5.0 g / L, NaCl 5.0 g / L, glucose 2.5 g / L, distilled water 1000 mL, adjust pH to 7.2, autoclave at 121 ℃ for 20 min, cooled at room temperature for later use.

Embodiment 2

[0017] Example 2 PCR and biochemical identification of tilapia-derived Streptococcus agalactiae attenuated strain YM001

[0018] The attenuated strain YM001 was identified by PCR identification method of tilapia-derived Streptococcus (Streptococcus iniae and Streptococcus agalactiae), API 20 Strep biochemical strip and VITEK 2 automatic microbial analyzer.

[0019] Double PCR rapid detection of Streptococcus iniae and Streptococcus agalactiae: PCR primers refer to published papers by Li Jiong et al. (2010) and Zlotkin et al. (1998). The size of the fragment amplified by cocci-specific primers was 296 bp. The PCR reaction reagent is a PCR kit from TaKaRa Company in Dalian, China, and the PCR system is as follows: 10× Ex Taq Buffer (Mg 2+ ) 5.0 μL, dNTP 2.0 μL, H1, H2, P1 and P2 primers 2.0 μL each, 2.0 μL DNA template (about 50 ng), 1.0 μL Takara Ex Taq (5 U / μL), 32.0 μL ddH 2 O, the total volume is 50 μL; the PCR reaction was carried out in the GeneAmp PCR system 9700...

Embodiment 3

[0022] Example 3: The median lethal dose LD of tilapia-derived Streptococcus agalactiae wild-type strain HN016 and attenuated strain YM001 to tilapia 50 determination

[0023] Use TSB to culture tilapia-derived wild-type strain HN016 and attenuated strain YM001, respectively, at 25-30 °C, shake the shaker for 18-24 hours, and use the plate colony counting method to count the bacteria in the liquid. Eight serial dilutions of the culture solution were performed with a 10-fold gradient, and 20 tilapias were infected by intraperitoneal injection of each concentration of the bacterial solution, 0.1 ml / tail; the same volume of TSB medium was injected intraperitoneally into tilapias in the control group, 0.1 ml / tail . Both the infected group and the control group were kept in an inflatable aquarium with 40 L of water, 2 / 3 of the water was changed every 2 days, the water temperature was controlled at 30-32 ℃, and the fish were fed twice a day in the morning and afternoon based...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an aquaculture animal disease control technology and in particular relates to a tilapia mossambica source streptococcus agalactiae low virulent strain and application thereof. The tilapia mossambica source streptococcus agalactiae low virulent strain is YM001 and is preserved in CCTCC (China Center For Type Culture Collection) with the preservation number of CCTCCM2014045. The tilapia mossambica source streptococcus agalactiae low virulent strain is subjected to activation culture and fermentation culture, bacterial cells of a 106-109CFU / mL low virulent strain YM001 and a sterile phosphate buffered solution are mixed as a low virulent live vaccine used for preventing and controlling a tilapia mossambica streptococcus disease, the injection medication concentration for each tilapia mossambica is 105-108CFU, the oral medication concentration for each tilapia mossambica is 108-109CFU, and the soaking medication concentration is 107-108CFU / mL. The invention relates to strain identification, toxicity test, toxicity return safety and stability, immunogenicity and immune protection effect of a low virulent strain, and the tilapia mossambica streptococcus disease vaccine prepared by adopting the low virulent strain is good in immune protection effect and strong in safety and stability.

Description

technical field [0001] The present invention relates to aquaculture animal disease control technology, specifically relates to Streptococcus agalactiae ( Streptococcus agalactiae ) infected tilapia streptococcosis immune control attenuated strain and its application. Background technique [0002] my country is the largest country in tilapia farming, and its annual output accounts for more than 50% of the world's total output. From 2001 to 2008, streptococcal infection occurred successively in tilapia farming in China, and caused a high mortality rate of 30% to 50% in individual farms. The main epidemic strain was Streptococcus iniae; 2009 to 2013 for 5 consecutive years , streptococcal disease has broken out in a large area of ​​tilapia aquaculture in China, and the incidence area is expanding year by year, and the morbidity and mortality are increasing year by year. et al., 2011; Maixin Lu et al., 2010; Zhu Jinglin et al., 2010; Zhou Suming, 2008). Calculated according ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N1/20A61K39/09A61P31/04C12R1/46
Inventor 陈明李莉萍王瑞甘西梁万文黄婷朱佳杰雷爱莹李健陈福艳
Owner GUANGXI ACADEMY OF FISHERY SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com